Biomarker & Intervention Discovery

Gastroparesis

This page lists 9 druggable gene targets, 44 approved or trial-tested drug candidates and 14 recent clinical trials for Gastroparesis, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Plain-language summary → New Treatments for Gastroparesis (2026): Drugs in Trials

US DALYs1.55MWHO GHE 2021 · all ages
Global DALYs17.03MWHO GHE 2021 · worldwide
US mortality53.1K deaths/yrWHO GHE 2021
Global mortality404.6K deaths/yrWHO GHE 2021 · worldwide
Spontaneous remissionIdiopathic gastroparesis: spontaneous resolution in ~30-40% at 5 years (NIDDK natural history study); diabetic…
Best-intervention remissionDietary modification + glycaemic optimisation: 50-60% improvement in symptoms; metoclopramide: 30-40% short-term…
Gap sizeLarge — gastric electrical stimulation and pyloromyotomy are underused; metoclopramide misuse is the dominant…
Primary barrierpractice/access
Full remission profile →
Research Tracker Chronic Disease Interventions Gastroparesis

Remission & chronicity

Spontaneous remission
Idiopathic gastroparesis: spontaneous resolution in ~30-40% at 5 years (NIDDK natural history study); diabetic gastroparesis: rarely remits, correlated with glycaemic control; postsurgical: highly variable
Best-intervention remission
Dietary modification + glycaemic optimisation: 50-60% improvement in symptoms; metoclopramide: 30-40% short-term symptom improvement (limited by side effects); gastric electrical stimulation (Enterra Therapy): 50-60% significant symptom improvement at 3-5 years in refractory patients; pyloric procedures (G-POEM): 75-80% short-term improvement
Gap size
Large — gastric electrical stimulation and pyloromyotomy are underused; metoclopramide misuse is the dominant pharmacotherapy problem
Primary barrier
practice/access
Metoclopramide (the only FDA-approved drug for gastroparesis since 1979) carries a black box warning for tardive dyskinesia with >12 weeks use; yet many patients are maintained long-term; gastric electrical stimulation (GES) is underutilised and restricted to few centres; domperidone (off-label, superior safety) inaccessible in US except via FDA expanded access

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

CNR1 63DRD2 372GHSR 39HTR3A 186HTR4 210KIT 125MLNR 30NOS1 70TACR1 77

CNR1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ADB-5'F-BUTINACA ↑ activates Mechanistic DGIdb
CANNABINOL ↑ activates Mechanistic DGIdb
NABILONE ↑ activates Mechanistic DGIdb
V24343 ↓ inhibits Mechanistic DGIdb
HEMOPRESSIN ? unclear Mechanistic DGIdb
VCE-004.3 ↓ inhibits Mechanistic DGIdb
NIMACIMAB ~ modulates Mechanistic DGIdb
OTENABANT ↓ inhibits Mechanistic DGIdb
CP55940 ↑ activates Mechanistic DGIdb
PEPCAN-12 ~ modulates Mechanistic DGIdb
GAT100 ~ modulates Mechanistic DGIdb
NP118809 ? unclear Mechanistic DGIdb
AZD2207 ↓ inhibits Mechanistic DGIdb
DRONABINOL ↑ activates Mechanistic DGIdb
TARANABANT ↓ inhibits Mechanistic DGIdb
ANANDAMIDE ↑ activates Mechanistic DGIdb
AM11542 ↑ activates Mechanistic DGIdb
ADB-BUTINACA ↑ activates Mechanistic DGIdb
RIMONABANT ↓ inhibits Mechanistic DGIdb
PF-514273 ↓ inhibits Mechanistic DGIdb
SAD448 ↑ activates Mechanistic DGIdb
HU-210 ↑ activates Mechanistic DGIdb
CHEMBL:CHEMBL498746 ? unclear Mechanistic DGIdb
TM39875 ↓ inhibits Mechanistic DGIdb
LY320135 ↓ inhibits Mechanistic DGIdb
IBIPINABANT ↓ inhibits Mechanistic DGIdb
AMAUROMINE ? unclear Mechanistic DGIdb
CANNABIDIOL ~ modulates Mechanistic DGIdb
COMPOUND 70 [PMID: 26161824] ↓ inhibits Mechanistic DGIdb
JD5037 ↓ inhibits Mechanistic DGIdb
MONLUNABANT ↑ activates Mechanistic DGIdb
ORG27569 ~ modulates Mechanistic DGIdb
AB-5'F-BUTINACA ↑ activates Mechanistic DGIdb
MRI-1867 ↑ activates Mechanistic DGIdb
VIP36 ↑ activates Mechanistic DGIdb
BMS-202 ↑ activates Mechanistic DGIdb
MDMB-FUBINACA ↑ activates Mechanistic DGIdb
NONABINE ↑ activates Mechanistic DGIdb
LIRAGLUTIDE ? unclear Mechanistic DGIdb
AM6545 ↓ inhibits Mechanistic DGIdb

Showing top 40 of 63 agents ranked by evidence tier.

DRD2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
LOXAPINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
MINAPRINE ↑ activates Mechanistic DGIdb
SULPIRIDE ↓ inhibits Mechanistic DGIdb
HALOPERIDOL DECANOATE ↓ inhibits Mechanistic DGIdb
ZIPRASIDONE MESYLATE ↓ inhibits Mechanistic DGIdb
METHYLDOPA ANHYDROUS ? unclear Mechanistic DGIdb
BENPERIDOL ↓ inhibits Mechanistic DGIdb
FLUSPIRILENE ↓ inhibits Mechanistic DGIdb
VERALIPRIDE ↓ inhibits Mechanistic DGIdb
CAFFEINE ? unclear Mechanistic DGIdb
SUMANIROLE ↑ activates Mechanistic 9.0 nM (Ki) DGIdb
ZIPRASIDONE ↓ inhibits Mechanistic DGIdb
METOCLOPRAMIDE HYDROCHLORIDE ? unclear Mechanistic DGIdb
LUMATEPERONE ↓ inhibits Mechanistic DGIdb
FLUPENTHIXOL ↓ inhibits Mechanistic DGIdb
PROCHLORPERAZINE ↓ inhibits Mechanistic DGIdb
PERAZINE ? unclear Mechanistic DGIdb
FLUPHENAZINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
ROPINIROLE ↑ activates Mechanistic DGIdb
RACLOPRIDE ↓ inhibits Mechanistic DGIdb
PROMAZINE ↓ inhibits Mechanistic DGIdb
[3H]PD128907 ↑ activates Mechanistic DGIdb
MORPHINE SULFATE ? unclear Mechanistic DGIdb
ALIZAPRIDE ↓ inhibits Mechanistic DGIdb
PHENYLTOLOXAMINE ? unclear Mechanistic DGIdb
LOXAPINE ↓ inhibits Mechanistic DGIdb
CABERGOLINE ↑ activates Mechanistic DGIdb
BREXPIPRAZOLE ↑ activates Mechanistic DGIdb
PALIPERIDONE ↓ inhibits Mechanistic DGIdb
APLINDORE FUMARATE ↑ activates Mechanistic DGIdb
APOMORPHINE ↑ activates Mechanistic DGIdb
CARIPRAZINE ↑ activates Mechanistic DGIdb
MOLINDONE ? unclear Mechanistic DGIdb
TIAPRIDE ↓ inhibits Mechanistic DGIdb
ZOTEPINE ↓ inhibits Mechanistic DGIdb
DOPAMINE ↑ activates Mechanistic DGIdb
XP21279 ? unclear Mechanistic DGIdb
PROMAZINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
VILAZODONE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
TRIFLUPROMAZINE ↓ inhibits Mechanistic DGIdb

Showing top 40 of 372 agents ranked by evidence tier.

GHSR

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ULIMORELIN HYDROCHLORIDE ↑ activates Mechanistic DGIdb
LIVER ENRICHED ANTIMICROBIAL PEPTIDE 2 ↓ inhibits Mechanistic DGIdb
DEHYDRATED ALCOHOL ? unclear Mechanistic DGIdb
[125I][HIS9]GHRELIN (HUMAN) ↑ activates Mechanistic DGIdb
PF-05190457 ↓ inhibits Mechanistic DGIdb
RELAMORELIN ↑ activates Mechanistic DGIdb
GHRP-6 ↑ activates Mechanistic DGIdb
CAPROMORELIN TARTRATE ↑ activates Mechanistic DGIdb
MACIMORELIN ACETATE ↑ activates Mechanistic DGIdb
IBUTAMOREN ↑ activates Mechanistic DGIdb
YIL781 ↓ inhibits Mechanistic DGIdb
MACIMORELIN ↑ activates Mechanistic DGIdb
[125I][TYR4]GHRELIN (HUMAN) ↑ activates Mechanistic DGIdb
ANAMORELIN ↑ activates Mechanistic DGIdb
TZP-102 ↑ activates Mechanistic DGIdb
TABIMORELIN ↑ activates Mechanistic DGIdb
SM-130,686 ↑ activates Mechanistic DGIdb
JMV3008 ↓ inhibits Mechanistic DGIdb
[125I]TYR-ALA-HEXARELIN ↑ activates Mechanistic DGIdb
L-692,429 ↑ activates Mechanistic DGIdb
GHRELIN ? unclear Mechanistic DGIdb
IPAMORELIN ? unclear Mechanistic DGIdb
IBUTAMOREN MESYLATE ↑ activates Mechanistic DGIdb
LENOMORELIN ↑ activates Mechanistic DGIdb
[35S]IBUTAMOREN ↑ activates Mechanistic DGIdb
BIM 28163 ↓ inhibits Mechanistic DGIdb
PF-6870961 ↓ inhibits Mechanistic DGIdb
ANAMORELIN HYDROCHLORIDE ↑ activates Mechanistic DGIdb
EXAMORELIN ↑ activates Mechanistic DGIdb
[D-ARG1,D-PHE5,D-TRP7,9,LEU11]SUBSTANCE P ↓ inhibits Mechanistic DGIdb
GSK1614343 ↓ inhibits Mechanistic DGIdb
CAPROMORELIN ↑ activates Mechanistic DGIdb
ABBOTT 14C ↓ inhibits Mechanistic DGIdb
PRALMORELIN ? unclear Mechanistic DGIdb
[18F]AQ-12 ↓ inhibits Mechanistic DGIdb
HM01 ↑ activates Mechanistic DGIdb
WFW-ISN-NH2 ↑ activates Mechanistic DGIdb
PF-5190457 ? unclear Mechanistic Open Targets
ULIMORELIN ? unclear Clinical Open Targets

HTR3A

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ALOSETRON ? unclear Mechanistic DGIdb
PUMOSETRAG ? unclear Mechanistic DGIdb
CLOZAPINE ? unclear Mechanistic 186.21 nM (Ki) DGIdb
FACINICLINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
RAMOSETRON ? unclear Mechanistic DGIdb
GRANISETRON ↓ inhibits Mechanistic 1.45 nM (Ki) DGIdb
RENZAPRIDE ↓ inhibits Mechanistic DGIdb
GRANISETRON HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
TEDATIOXETINE ? unclear Mechanistic DGIdb
DDP-225 ? unclear Mechanistic DGIdb
PALONOSETRON HYDROCHLORIDE ? unclear Mechanistic DGIdb
TROPISETRON ↓ inhibits Mechanistic 2.7 nM (Ki) DGIdb
ITASETRON ? unclear Mechanistic DGIdb
ROCURONIUM ? unclear Mechanistic DGIdb
OCTOPAMINE ? unclear Mechanistic 24.0 nM (EC50) DGIdb
MOSAPRIDE ↓ inhibits Mechanistic DGIdb
AZASETRON ? unclear Mechanistic DGIdb
DEXFENFLURAMINE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
RAMOSETRON HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
MIANSERIN ? unclear Mechanistic DGIdb
[3H]TYRAMINE ? unclear Mechanistic DGIdb
METOCLOPRAMIDE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
PANCOPRIDE ? unclear Mechanistic DGIdb
LERISETRON ? unclear Mechanistic 0.36 nM (Ki) DGIdb
VORTIOXETINE HYDROBROMIDE ? unclear Mechanistic DGIdb
HALOPERIDOL DECANOATE ? unclear Mechanistic DGIdb
PROCAINE ? unclear Mechanistic DGIdb
BIMU 1 ? unclear Mechanistic DGIdb
METITEPINE ? unclear Mechanistic DGIdb
ZIMELDINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
LITOXETINE ? unclear Mechanistic DGIdb
DOLASETRON MESYLATE ↓ inhibits Mechanistic DGIdb
LEVETIRACETAM ? unclear Mechanistic DGIdb
MIRTAZAPINE ? unclear Mechanistic DGIdb
ALOSETRON HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
DOLASETRON ? unclear Mechanistic DGIdb
CILANSETRON ↓ inhibits Mechanistic DGIdb
ONDANSETRON HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
ZATOSETRON MALEATE ? unclear Mechanistic DGIdb
LINTOPRIDE ? unclear Mechanistic DGIdb

Showing top 40 of 186 agents ranked by evidence tier.

HTR4

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
MOSAPRIDE ↑ activates Mechanistic DGIdb
TROPISETRON ↓ inhibits Mechanistic DGIdb
NARONAPRIDE ↑ activates Mechanistic DGIdb
VILAZODONE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
RS 100235 ↓ inhibits Mechanistic DGIdb
VELUSETRAG ↑ activates Mechanistic DGIdb
ZACOPRIDE ↑ activates Mechanistic DGIdb
TEGASEROD ↑ activates Mechanistic DGIdb
TD-8954 ↑ activates Mechanistic DGIdb
CISAPRIDE ↑ activates Mechanistic 29.0 nM (Ki) DGIdb
PF-04995274 ↑ activates Mechanistic DGIdb
REVEXEPRIDE ↑ activates Mechanistic DGIdb
BIMU 1 ↑ activates Mechanistic DGIdb
LINTOPRIDE ? unclear Mechanistic DGIdb
ZOLMITRIPTAN ? unclear Mechanistic DGIdb
DAU 6285 ↓ inhibits Mechanistic DGIdb
Α-METHYL-5-HT ↑ activates Mechanistic DGIdb
SULPIRIDE ↑ activates Mechanistic DGIdb
PRX-03140 ↑ activates Mechanistic DGIdb
CLEBOPRIDE ↑ activates Mechanistic DGIdb
GR 113808 ↓ inhibits Mechanistic DGIdb
CHEMBL:CHEMBL401607 ? unclear Mechanistic DGIdb
ACETAMINOPHEN ? unclear Mechanistic DGIdb
SB 203186 ↓ inhibits Mechanistic DGIdb
PIBOSEROD ↓ inhibits Mechanistic 0.631 nM (IC50) DGIdb
RENZAPRIDE ↑ activates Mechanistic DGIdb
BIMU 8 ↑ activates Mechanistic DGIdb
PRUCALOPRIDE ↑ activates Mechanistic 7.5 nM (Ki) DGIdb
FLUOXETINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
PRUCALOPRIDE SUCCINATE ↑ activates Mechanistic DGIdb
TD-2749 ? unclear Mechanistic DGIdb
METITEPINE ? unclear Mechanistic DGIdb
RS 39604 ↓ inhibits Mechanistic DGIdb
USMARAPRIDE ? unclear Mechanistic DGIdb
RELENOPRIDE ↑ activates Mechanistic DGIdb
GR 125487 ↓ inhibits Mechanistic DGIdb
DA-6886 ? unclear Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
MIANSERIN ? unclear Mechanistic DGIdb
ZIMELDINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb

Showing top 40 of 210 agents ranked by evidence tier.

KIT

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
OSI-930 ? unclear Mechanistic DGIdb
CHMFL-KIT-8140 ↓ inhibits Mechanistic DGIdb
IMATINIB ↓ inhibits Mechanistic DGIdb
PEXIDARTINIB ↓ inhibits Mechanistic DGIdb
REGORAFENIB ↓ inhibits Mechanistic DGIdb
SORAFENIB ↓ inhibits Mechanistic DGIdb
TANDUTINIB ↓ inhibits Mechanistic DGIdb
RIPRETINIB ↓ inhibits Mechanistic DGIdb
XL820 ↓ inhibits Mechanistic DGIdb
VATALANIB ↓ inhibits Mechanistic DGIdb
PAZOPANIB HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
ENMD-2076 ↓ inhibits Mechanistic DGIdb
TRAMETINIB DIMETHYL SULFOXIDE ? unclear Mechanistic DGIdb
PEMBROLIZUMAB ? unclear Mechanistic DGIdb
VELZATINIB ↓ inhibits Mechanistic DGIdb
PONATINIB ? unclear Mechanistic DGIdb
CABOZANTINIB S-MALATE ↓ inhibits Mechanistic DGIdb
CRIZOTINIB ? unclear Mechanistic DGIdb
LABUXTINIB ↓ inhibits Mechanistic DGIdb
BAY 61-3606 ? unclear Mechanistic DGIdb
CATEQUENTINIB ↓ inhibits Mechanistic DGIdb
PLX5622 ↓ inhibits Mechanistic DGIdb
RISVODETINIB ↓ inhibits Mechanistic DGIdb
VENETOCLAX ? unclear Mechanistic DGIdb
XL999 ? unclear Mechanistic DGIdb
EDICOTINIB ↓ inhibits Mechanistic DGIdb
AMUVATINIB ↓ inhibits Mechanistic DGIdb
ILORASERTIB ↓ inhibits Mechanistic DGIdb
AC710 ↓ inhibits Mechanistic DGIdb
LENVATINIB ? unclear Mechanistic DGIdb
AVAPRITINIB ↓ inhibits Mechanistic DGIdb
MOTESANIB ↓ inhibits Mechanistic DGIdb
SU-11652 ↓ inhibits Mechanistic DGIdb
JNJ-28312141 ↓ inhibits Mechanistic DGIdb
RG-1530 ↓ inhibits Mechanistic DGIdb
MASITINIB ↓ inhibits Mechanistic DGIdb
SERALUTINIB ↓ inhibits Mechanistic DGIdb
FAMITINIB ↓ inhibits Mechanistic DGIdb
MIDOSTAURIN ↓ inhibits Mechanistic DGIdb
SORAFENIB TOSYLATE ↓ inhibits Mechanistic DGIdb

Showing top 40 of 125 agents ranked by evidence tier.

MLNR

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
MITEMCINAL ? unclear Mechanistic DGIdb
MOTILIN-(1-13) (HUMAN) ↑ activates Mechanistic DGIdb
MOTILIN-(1-12) (HUMAN) ↑ activates Mechanistic DGIdb
[L-BPA5,ILE13]MOTILIN (HUMAN) ↑ activates Mechanistic DGIdb
CAMICINAL ↑ activates Mechanistic DGIdb
MOTILIN ↑ activates Mechanistic DGIdb
MITEMCINAL FUMARATE ↑ activates Mechanistic DGIdb
[BPA1,ILE13]MOTILIN (HUMAN) ↑ activates Mechanistic DGIdb
ME36 ↑ activates Mechanistic DGIdb
OHM-11526 ↓ inhibits Mechanistic DGIdb
[PHE3,LEU13]MOTILIN (HUMAN) ↑ activates Mechanistic DGIdb
ATILMOTIN ↑ activates Mechanistic DGIdb
ME67 ↑ activates Mechanistic DGIdb
MOTILIN-(1-19) (HUMAN) ↑ activates Mechanistic DGIdb
[125I]MOTILIN (HUMAN) ↑ activates Mechanistic DGIdb
ALEMCINAL ↑ activates Mechanistic DGIdb
ROXITHROMYCIN ↑ activates Mechanistic DGIdb
KOS-2187 ? unclear Mechanistic DGIdb
DS-3801B FREE BASE ↑ activates Mechanistic DGIdb
KOS1326 ↑ activates Mechanistic DGIdb
EM-523 ↑ activates Mechanistic DGIdb
AZITHROMYCIN ↑ activates Mechanistic DGIdb
[D-BPA5,ILE13]MOTILIN (HUMAN) ↑ activates Mechanistic DGIdb
[NLEU13,GLU14]MOTILIN (HUMAN) ↑ activates Mechanistic DGIdb
MA-2029 ↓ inhibits Mechanistic DGIdb
[LEU13]MOTILIN (HUMAN) ↑ activates Mechanistic DGIdb
ME4 ↑ activates Mechanistic DGIdb
ERYTHROMYCIN ↑ activates Mechanistic DGIdb
MOTILIN-(2-22) (HUMAN) ↑ activates Mechanistic DGIdb
MOTILIN-(1-11) (HUMAN) ↑ activates Mechanistic DGIdb

NOS1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
NXN-188 ? unclear Mechanistic DGIdb
TIRAPAZAMINE ? unclear Mechanistic DGIdb
PRAZOSIN ? unclear Mechanistic DGIdb
RECOMBINANT NEUROTROPHIC FACTOR ? unclear Mechanistic DGIdb
CAFFEINE ? unclear Mechanistic DGIdb
NIMESULIDE ? unclear Mechanistic DGIdb
TESTOSTERONE ? unclear Mechanistic DGIdb
CARVEDILOL ? unclear Mechanistic DGIdb
IDOXIFENE ? unclear Mechanistic DGIdb
THERAPEUTIC CORTICOSTEROID ? unclear Mechanistic DGIdb
ADJUVANT ? unclear Mechanistic DGIdb
ACETAZOLAMIDE ? unclear Mechanistic DGIdb
3-BROMO-7NI ↓ inhibits Mechanistic DGIdb
L-NNA ↓ inhibits Mechanistic DGIdb
GREEN TEA EXTRACT ? unclear Mechanistic DGIdb
GW274150 ↓ inhibits Mechanistic DGIdb
SIROLIMUS ? unclear Mechanistic DGIdb
BUTHIONINE SULFOXIMINE ? unclear Mechanistic DGIdb
PRASTERONE ? unclear Mechanistic DGIdb
ZZL-7 ? unclear Mechanistic DGIdb
FLUOROURACIL ? unclear Mechanistic DGIdb
PRAVASTATIN SODIUM ? unclear Mechanistic DGIdb
LIOTHYRONINE ? unclear Mechanistic DGIdb
PHENYLEPHRINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
THIOURACIL ? unclear Mechanistic DGIdb
ANTIESTROGEN ? unclear Mechanistic DGIdb
EPIRUBICIN ? unclear Mechanistic DGIdb
ENALAPRIL MALEATE ? unclear Mechanistic DGIdb
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic DGIdb
POLYESTRADIOL PHOSPHATE ? unclear Mechanistic DGIdb
BACLOFEN ? unclear Mechanistic DGIdb
SODIUM CHLORIDE ? unclear Mechanistic DGIdb
7NI ↓ inhibits Mechanistic DGIdb
FULVESTRANT ? unclear Mechanistic DGIdb
STAUROSPORINE ? unclear Mechanistic DGIdb
DIURETIC ? unclear Mechanistic DGIdb
GINKGO ? unclear Mechanistic DGIdb
TILARGININE ↓ inhibits Mechanistic DGIdb
PENICILLIN ANTIBIOTIC ? unclear Mechanistic DGIdb
NONSTEROIDAL ANTIINFLAMMATORY DRUG ? unclear Mechanistic DGIdb

Showing top 40 of 70 agents ranked by evidence tier.

TACR1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
R116031 ↓ inhibits Mechanistic DGIdb
SUBSTANCE P-(4-11) ↑ activates Mechanistic DGIdb
[125I]SP (HUMAN, MOUSE, RAT) ↑ activates Mechanistic DGIdb
FK-888 ↓ inhibits Mechanistic DGIdb
ZD6021 ↓ inhibits Mechanistic DGIdb
FOSNETUPITANT CHLORIDE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
CHEMBL:CHEMBL2203705 ? unclear Mechanistic DGIdb
[3H]SP (HUMAN, MOUSE, RAT) ↑ activates Mechanistic DGIdb
NEUROPEPTIDE K ↑ activates Mechanistic DGIdb
SERLOPITANT ↓ inhibits Mechanistic DGIdb
SUBSTANCE P-OME ↑ activates Mechanistic DGIdb
FK 224 ↓ inhibits Mechanistic DGIdb
TRADIPITANT ↓ inhibits Mechanistic DGIdb
L-733,060 ↓ inhibits Mechanistic DGIdb
[18F]SPA-RQ ↓ inhibits Mechanistic DGIdb
L-703,606 ↓ inhibits Mechanistic DGIdb
FR139317 ? unclear Mechanistic DGIdb
ORVEPITANT ? unclear Mechanistic DGIdb
EZLOPITANT ↓ inhibits Mechanistic DGIdb
THERAPEUTIC CYTOKINE ? unclear Mechanistic DGIdb
SEPTIDE ↑ activates Mechanistic DGIdb
CASOPITANT ↓ inhibits Mechanistic DGIdb
CP-122721 ? unclear Mechanistic DGIdb
VAPREOTIDE ? unclear Mechanistic DGIdb
L-732,138 ↓ inhibits Mechanistic DGIdb
ROLAPITANT ↓ inhibits Mechanistic DGIdb
OSANETANT ↓ inhibits Mechanistic DGIdb
DAPITANT ? unclear Mechanistic DGIdb
SUBSTANCE P ↑ activates Mechanistic DGIdb
MAROPITANT CITRATE ↓ inhibits Mechanistic DGIdb
ELEDOISIN ↑ activates Mechanistic DGIdb
SELEGILINE ? unclear Mechanistic DGIdb
LANEPITANT ↓ inhibits Mechanistic DGIdb
ARGIPRESSIN ? unclear Mechanistic DGIdb
RP67580 ↓ inhibits Mechanistic DGIdb
CP 99994 ↓ inhibits Mechanistic DGIdb
T2328 ↓ inhibits Mechanistic DGIdb
FIGOPITANT ↓ inhibits Mechanistic DGIdb
TAK-637 ↓ inhibits Mechanistic DGIdb
VESTIPITANT MESYLATE ? unclear Mechanistic DGIdb

Showing top 40 of 77 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Gastroparesis: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis Completed
NCT05270460 Phase: 2 Started: 2022-03-09

This is a randomized, double-blind, placebo-controlled study that will compare the effect of 2 different dosage regimens of PCS12852 on gastric emptying time to placebo in both idiopathic gastroparesis (IG) and diabetic gastroparesis (DG) patients.

Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis Completed
NCT06836557 Phase: 3 Started: 2024-01-09

This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.

Different Doses of Naronapride vs. Placebo in Gastroparesis Completed
NCT05621811 Phase: 2 Started: 2023-01-03

This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 10, 20, or 40 mg Naronapride vs...

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis Completed
NCT04028492 Phase: 3 Started: 2019-08-20

To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis. Completed
NCT06899217 Phase: 2 Started: 2025-01-29

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastropar...

Growth Hormone for the Treatment of Gastroparesis Recruiting
NCT06803589 Phase: Early 1 Started: 2024-10-22

The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis Completed
NCT05832151 Phase: 2 Started: 2023-03-27

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to ...

Pioglitazone for Idiopathic Gastroparesis Completed
NCT04300127 Phase: Early 1 Started: 2019-10-24

The principal objective of this pilot study will be to evaluate whether 8 weeks of treatment of pioglitazone will improve symptoms as measured by the Gastrointestinal Symptom Index (GCSI) in patients with Idiopathic Gastroparesis.

Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis Completed
NCT02970968 Phase: 2 Started: 2016-11

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will be randomized to one of two treatment groups, active or placebo.

Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia Completed
NCT03941288 Phase: 2 Started: 2019-09-04

Researchers are looking at the effects of a cannabidiol medication on stomach function in people with gastroparesis (a paralyzed stomach) and people with dyspepsia (an upset stomach caused by improper functioning of the stomach's muscles or nerves).

Buspirone for Early Satiety and Symptoms of Gastroparesis Completed
NCT03587142 Phase: 2 Started: 2019-08-27

This study evaluates whether the study medication, buspirone, an antianxiety drug, improves the symptoms of gastroparesis in patients with gastroparesis symptoms and at least moderately severe symptoms of fullness and/or inability to eat a full meal. Half the patients will receive buspirone and half...

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis Completed
NCT03544229 Phase: 2 Started: 2018-10-14

The purpose of this study is to assess the efficacy and safety of treatment with 2 dose levels of TAK-906 in adult participants with gastroparesis compared with placebo during 12 weeks of treatment.

A Study of CNSA-001 in Women With Diabetic Gastroparesis Completed
NCT03712124 Phase: 2 Started: 2019-02-27

This study evaluates CNSA-001 (sepiapterin) in the treatment of women with moderate to severe diabetic gastroparesis. Participants will be randomized in a ratio of 1:1 to receive CNSA-001 20 (milligrams) mg/kilogram (kg)/day or placebo. All participants will receive the standard of care for diabetic...

Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants Completed
NCT03281577 Phase: 2 Started: 2018-01-02

The purpose of this study is to evaluate the dose-dependent effects of TAK-954 on gastric emptying time of solids in participants with diabetic or idiopathic gastroparesis assessed by scintigraphy.

Agents Found By Disease-Level Search

Searched directly from “Gastroparesis” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 9-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

44 agents shown (approved or with trial evidence) — 37 not found by the gene-target search above.

Gastric emptying of carbohydrate-rich beverageNOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT02753010 NCT02753010 NCT02753010

GSK962040 (50 mg)NOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT01039805 NCT00861809

Erythromycin

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01659619 NCT02005029

PancreaticoduodenectomyNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT02246205 NCT06413888

Domperidone

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01696734 NCT04699591

TAK-906 MaleateNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT03544229 NCT03268941

Velusetrag

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02267525

Nortriptyline HydrochlorideNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00765895

HydrocortisoneNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01460615

GSK962040 (75 mg)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01039805

Tradipitant

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT06836557

CIN-102 Dose 15mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06899217

CIN-102 Dose 10mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06899217

13C-uracilNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01677338

99mTc sulfur colloidNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01677338

Buspirone

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03587142

NizatidineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02232308

LisinoprilNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02232308

GES + Upper endoscopyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07526935

GES on + Upper endscopyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07526935

GES off + G-POEMNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07526935

GES on + G-POEMNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07526935

ANOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01267071

BNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01267071

magnetogastrogramNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03176927

G-POEMNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06372132

Atmo gas capsuleNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04977063

SmartPillNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04977063

per oral pylorotomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02779920

Medtronic 780G AIDNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07287943

Magnetically Controlled Capsule EndoscopyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05004012

PCS12852NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05270460

PyloromyotomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04696159

PPPD with Braun anastomosisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01787955

conventional PPPDNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01787955

Aprepitant

· 1 trial · source: ClinicalTrials.gov
NCT01149369

Cannabidiol

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03941288

mitemcinal (GM-611)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00050882

Gastric AlimetryNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06401746

MetaclopramideNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03268941

dietary treatment: food of small particle sizeNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01557296

postprandial plasma glucoseNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01557296

camicinal (GSK962040)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01039974

KetoconazoleNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01039974

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.